Zhang, Wu <br/><br/>
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Aug 2007 
 - 3712-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2006.08.8021  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Antibody-Dependent Cell Cytotoxicity<br/>Antineoplastic Agents--adverse effects<br/>Cetuximab<br/>Colorectal Neoplasms--drug therapy<br/>Disease-Free Survival<br/>ErbB Receptors--metabolism<br/>Female<br/>Genotype<br/>Humans<br/>Male<br/>Middle Aged<br/>Polymorphism, Genetic<br/>Receptors, IgG--genetics<br/>Survival Rate